Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. (PROF) is a commercial-stage medical device company that regularly issues news on its AI-powered, MRI-guided, incision-free therapies for tissue ablation. The company’s updates frequently center on its TULSA-PRO system and the TULSA Procedure™, which are used to treat prostate cancer and benign prostatic hyperplasia (BPH) using robotically controlled, transurethral ultrasound under real-time MRI guidance.
News coverage for Profound often highlights new clinical milestones, such as first commercial TULSA-PRO cases at major academic hospitals, expansion of TULSA-PRO programs at imaging suites, and recognition of clinical trial data comparing the TULSA Procedure to robotic radical prostatectomy. Releases also describe real-world experience across the prostate disease spectrum, including cancer-only, hybrid cancer and BPH cases, BPH-only patients, and salvage therapy for radio-recurrent localized prostate cancer.
Investors and clinicians following PROF can also expect announcements on regulatory and commercial developments. These include exclusive distribution and supply agreements for TULSA-PRO and Sonalleve in regions such as Canada, Saudi Arabia, Australia and New Zealand, as well as financing transactions like registered direct offerings and private placements used to support sales expansion, research and development, and working capital.
In addition, Profound’s news flow covers product enhancements such as the TULSA-AI® Volume Reduction module for BPH, new clinical data presented at medical meetings, and updates on the installed base and qualified sales pipeline for TULSA-PRO systems. This page aggregates these company-issued releases and related coverage, offering a single location to review the latest developments affecting Profound Medical’s technologies, commercial footprint and capital markets activity.
Profound (NASDAQ:PROF) reported its year-end TULSA-PRO installed base reached 78 systems as of December 31, 2025, exceeding its goal of 75 installs for 2025. The company also said its qualified sales pipeline grew to 97 new systems classified in the "Verify, Negotiate and Contracting" stages at year-end. Management linked the larger installed base to expectations of higher patient treatment rates and growth in recurring revenue tied to procedures, and noted upcoming Q4 and full-year 2025 financial results due near the end of February 2026.
Profound Medical (NASDAQ:PROF) announced that Johns Hopkins Hospital treated its first commercial (non‑clinical‑trial) prostate cancer patient using the TULSA-PRO system on Jan 6, 2026.
The milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI (iMRI) suite and underscores adoption of MRI-guided, incision‑free prostate ablation. The company notes TULSA-PRO uses robotically controlled directional ultrasound plus real‑time MRI thermography to target tissue, aiming for no procedural blood loss, no overnight stay, and reduced side effects versus surgery or radiation. The summary also cites prior participation in the TACT pivotal trial that led to FDA clearance.
Profound Medical (NASDAQ:PROF) closed a private placement on Dec 30, 2025, issuing 921,428 common shares at US$7.00 per share for aggregate gross proceeds of approximately US$6.45 million.
The issued shares carry a Canadian resale hold period of four months plus one day. The company intends to use net proceeds for sales and marketing, working capital, R&D, strategic transactions and general corporate purposes. Profound agreed to file a U.S. registration statement to register resale of the shares within four months of closing.
Profound Medical (NASDAQ:PROF) increased the size of its private placement announced Dec 19, 2025. The Offering will now raise gross proceeds of up to US$6.45 million through issuance of up to 921,428 common shares at US$7.00 per share. Closing is expected on or prior to December 30, 2025. Shares sold in the Offering will be subject to a four months plus one day hold period from closing. The company intends to use net proceeds for sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes. No securities will be sold to U.S. purchasers and the securities will not be registered under the U.S. Securities Act.
Profound Medical (NASDAQ:PROF) closed a registered direct offering of 5,142,870 common shares at $7.00 per share for gross proceeds of approximately $36 million before fees and expenses. The offering had no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.
The company said net proceeds will fund sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes. Konik Capital Partners acted as exclusive placement agent. The offering was made from an effective Form S-3 shelf declared effective on Dec 4, 2025.
Profound expects to close a related private placement to Canadian purchasers on or before Dec 30, 2025, subject to approvals including conditional Toronto Stock Exchange approval; those securities will not be offered to U.S. persons.
Profound Medical (Nasdaq:PROF) announced a financing package of up to $40 million consisting of a $36 million registered direct offering (5,142,857 common shares at $7.00 per share) and a subsequent Canadian private placement of up to $4 million (571,428 common shares at $7.00 per share).
The registered direct offering is expected to close on or about December 22, 2025, subject to customary conditions; the private placement closing is expected on or prior to December 30, 2025 and is subject to Toronto Stock Exchange conditional approval and a four-month-plus-one-day hold period for those shares.
Gross proceeds to the company are expected to be approximately $36 million before placement agent fees and expenses, and net proceeds are planned for sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes.
Profound Medical (NASDAQ:PROF) highlighted RSNA recognition for perioperative data from the CAPTAIN randomized controlled trial comparing MRI-guided TULSA versus robotic radical prostatectomy, presented Dec 4, 2025.
Key points: CAPTAIN successfully recruited to target as a randomized trial; the presentation received an RSNA Cum Laude award (one of six awards, top 5% of posters); reported perioperative data show robotic RP patients take ~three weeks to recover to the same state TULSA patients reach the next day; TULSA has no blood loss and no overnight stay.
Profound Medical (NASDAQ:PROF) will launch the TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) at RSNA, Nov 30–Dec 4, 2025, and present new TULSA-PRO clinical data at RSNA and SUO (Dec 2–5, 2025).
The AI-powered module is described as optimizing BPH treatment workflow, reducing procedure times, and enabling multiple same-day cases with existing hardware and reimbursement codes. Company cites pilot trial success, CAPTAIN perioperative data comparing TULSA favorably to robotic prostatectomy on blood loss, length of stay, post-op pain and recovery, and projects a total available prostate-disease market of ~600,000 patients annually.
Profound Medical (NASDAQ:PROF) announced that The Hong Center Scottsdale, led by Dr. Y. Mark Hong, reached a world-first milestone of 200 independent TULSA Procedures performed by a urologist without radiologist involvement on Nov 18, 2025. The milestone highlights a urology-led, MRI-guided, incision-free workflow using the TULSA-PRO system, which offers real-time MRI thermography, autonomous temperature control, and robotically controlled directional ultrasound to ablate prostate tissue while protecting nearby structures.
The announcement notes consistent high-volume experience across whole-gland, focal, BPH and salvage cases, with no procedural blood loss or hospitalization reported and an emphasis on preserved urinary and sexual function.
Profound Medical (NASDAQ:PROF) reported record Q3 2025 revenue of $5.3M, up 87% YoY, driven by $4.1M recurring non-capital revenue and $1.2M capital equipment sales. Gross margin expanded 1,119 bps to 74.3% on manufacturing efficiency. Installed base reached 70 systems with a qualified pipeline of 93 new systems; the company expects at least 75 installs by year-end. Q3 net loss improved to $8.0M ($0.26/share) from $9.4M a year ago. Cash was approximately $24.8M as of September 30, 2025. The company announced new distribution agreements and clinical program milestones to support adoption.